14 citations
,
June 2020 in “Journal of the American Academy of Dermatology” Global collaboration in dermatology improved data sharing and patient care during COVID-19.
8 citations
,
July 2023 in “Frontiers in Pharmacology” Cepharanthine shows promise as a COVID-19 treatment.
6 citations
,
December 2022 in “Journal of Infection” The ACE1 gene variant doesn't affect long-COVID symptoms.
February 2024 in “PubMed” More people experience hair loss after recovering from COVID-19 in hospitals than in outpatient settings.
2 citations
,
October 2020 in “Journal of Pharmacy And Bioallied Sciences” Hydroxychloroquine and chloroquine are not recommended for COVID-19 treatment due to insufficient evidence and safety concerns.
4 citations
,
November 2023 in “PLoS ONE” Interest in long-COVID symptoms in Japan increased with COVID-19 case peaks, especially for hair loss, cough, smell/taste issues, and headache.
52 citations
,
March 2022 in “Biology of Sex Differences” Females have stronger immune responses to COVID-19 than males, leading to better outcomes.
16 citations
,
March 2022 in “Journal of Infection” Booster doses of Covaxin improve protection against the Omicron variant.
6 citations
,
March 2022 in “Frontiers in drug discovery” Some small molecule antivirals show promise against COVID-19, but more research is needed to understand and improve them.
5 citations
,
December 2021 in “Journal of Cosmetic Dermatology” QR678 Neo® hair growth treatment is effective for hair loss caused by Covid-19.
170 citations
,
September 2020 in “Viruses” Drug repositioning offers a cost-effective, lower-risk way to treat diseases and pandemics like COVID-19.
2 citations
,
October 2022 in “Current Dermatology Reports” People on immune-modifying skin disease treatments may have a weaker antibody response to COVID-19 vaccines but often improve after the second dose.
The study concludes that long COVID recovery involves time, various treatments, and a strong patient-provider relationship.
32 citations
,
March 2021 in “Journal of cosmetic dermatology (Print)” COVID-19 infection may trigger alopecia areata in some patients.
22 citations
,
October 2021 in “Dermatologic Therapy” COVID-19 may cause temporary hair loss in some people.
April 2024 in “Public health” Vaccination and timely treatment reduce the risk of long COVID.
3 citations
,
May 2021 in “Dermatologic Clinics” COVID-19 changed dermatology by increasing telemedicine and highlighting healthcare disparities.
28 citations
,
January 2021 in “Skin appendage disorders” COVID-19 may cause early hair loss similar to classic temporary hair loss, with further research needed.
4 citations
,
March 2021 in “International Journal of Dermatology” COVID-19 and related stress may increase hair loss known as Telogen effluvium.
2 citations
,
August 2022 in “Clinical Case Reports” A 17-year-old girl had severe, on-and-off hair loss, likely due to COVID-19. She was treated with Vitamin D3, biotin, and other supplements, and saw some improvement within a month.
October 2022 in “Research, Society and Development” Hair loss is a symptom of long COVID and can be treated with a protein-rich diet.
7 citations
,
September 2020 in “Journal of Cosmetic Dermatology” Minoxidil and Finasteride are the most popular hair loss treatments, with rising interest in other options, and economic or health crises can change what treatments people prefer.
January 2024 in “American journal of clinical dermatology” Ritlecitinib is safe and well-tolerated for treating alopecia areata in patients aged 12 and older.
COVID-19 may trigger or worsen rapid hair loss in alopecia areata.
4 citations
,
March 2023 in “PubMed” Stress and COVID-19 can worsen hair loss conditions like alopecia areata.
January 2025 in “SKIN The Journal of Cutaneous Medicine” Some patients on Baricitinib for alopecia areata lost response, often linked to longer and more severe initial conditions.
Migrant and minority communities face higher rates of alopecia due to genetic, environmental, and cultural factors, needing better healthcare access and culturally aware treatments.
June 2025 in “Голова и шея.” COVID-19-related hair loss may be linked to blood flow disorders and inflammation.
January 2025 in “Annals of Dermatology” COVID-19 vaccination may slightly increase the risk of hair loss, but benefits outweigh this risk.
April 2024 in “Clinical dermatology review (Print)” Most women aged 20-40 in the study lost hair diffusely and in volume over 6 weeks to 6 months, mainly due to telogen effluvium, often without a clear cause.